GLP-1, GIP, AND AMYLIN RECEPTOR TRIAGONISTS

PE0016712026A1Pending Publication Date: 2026-08-19NOVO NORDISK AS

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: PE2026001599
Authority / Receiving Office: PE · PE
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-11-29
Filing Date: 2024-11-29
Publication Date: 2026-08-19

Application Information

Patent Timeline

29 Nov 2024

Priority

29 Nov 2024

Application

PE2026001599

19 Aug 2026

Publication

PE0016712026A1

IPC: C07K14/575; A61K38/00; A61K38/08; A61K38/16; A61K38/26; A61P1/04; A61P1/16; A61P3/00; A61P3/04; A61P3/10; A61P43/00; C07D401/12; C07D401/14; C07D471/04; C07K7/06; C07K7/08; C07K14/585; C07K14/605

CPC: A61K38/08; C07K14/575; C07K14/605; C07K7/06; C07K7/08; C07K14/585; A61K38/26; A61P3/04

Inventors: KRUSE Thomas; LAU Jesper F.

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to a GLP-1 / GIP / amylin receptor triagonist. This GLP-1 / GIP / amylin receptor triagonist has improved pharmacokinetic properties and may be suitable for once-weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1 / GIP / amylin receptor triagonist and may be used as a medicament for the treatment of overweight, obese, and associated comorbidities.

Need to check novelty before this filing date? Find Prior Art